KURA ONCOLOGY, INC. Payment for Debt Extinguishment or Debt Prepayment Cost
KURA ONCOLOGY, INC. (KURA) reported Payment for Debt Extinguishment or Debt Prepayment Cost of $611.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2024-02-27.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtExtinguishmentCosts · last filed 2024-02-27
- KURA ONCOLOGY, INC. payment for debt extinguishment or debt prepayment cost for the quarter ending 2021-12-31 was $0.00.
- KURA ONCOLOGY, INC. payment for debt extinguishment or debt prepayment cost for the quarter ending 2021-09-30 was $0.00.
- KURA ONCOLOGY, INC. payment for debt extinguishment or debt prepayment cost for fiscal 2021 was $611.00K.
| Period end | Payment for Debt Extinguishment or Debt Prepayment Cost 3 month | Payment for Debt Extinguishment or Debt Prepayment Cost 6 month | Payment for Debt Extinguishment or Debt Prepayment Cost 9 month | Payment for Debt Extinguishment or Debt Prepayment Cost 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $0.00 derived: sum of 2 quarters · filed 2024-02-27 | $611.00K 10-K · filed 2024-02-27 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $611.00K 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $611.00K 10-Q · filed 2022-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |